Cell & gene therapy

Despite their potential to change the face of medicine, reducing long-term medical costs and curing diseases, innovations in cell and gene therapy face regulatory issues, along with the need for long-term studies, before market acceptance can be achieved.  

Research in this important field is undergoing rapid growth. However, due to the significant costs and timescales involved in gaining approval, effective IP strategies must be established to protect investment and maintain market position. 

Working across academic research institutes, SMEs and large multinationals, HGF’s specialist cell and gene therapy attorneys tap into their vast experience to develop robust and tailored IP strategies for their clients in this field. The team has extensive experience in helping organisations protect and exploit their IP and assess their freedom to operate.

Latest updates

Where Does the Real IP Value Lie in AI-Enabled Life Sciences?

After attending the BioTechX conference in Basel last week, talking to people working across pharma, biotech, AI, software, laboratory automation and data management, my main takeaway was clear: the conversation …

Read article

When AI Designs the Ingredient: Who Controls the Data, the Model and the Discovery?

AI-enabled discovery has drawn significant attention in pharmaceutical R&D, but its impact is extending into other industries, across ingredients, food, flavour, fragrance and industrial biotechnology. As AI models advance, the …

Read article

Protecting the AI Drug Discovery Ecosystem: Building an IP Stack Around Targets, Molecules and Medicines

Despite the considerable costs and effort in target identification, candidate generation, selection and advancement to clinical trials, 90% of candidates that enter clinical trials during drug discovery fail (Sun D, …

Read article

Agritech Thymes: UK-EU SPS agreement – what does it mean for plant breeders?

Since Brexit, the UK agrifood sector has faced difficulties, largely due to the requirement for additional certifications and controls, such as phytosanitary certificates and border checks. This has had a …

Read article

How Low Can You Go? T 0137/24, Percentage Sequence Identity Claims and Divergent EPO and USPTO Approaches

Key takeaways Increasing percentage sequence identity thresholds may be selected from a disclosed convergent list without adding matter, provided the amendment does not create a new technical combination; Broader percentage …

Read article
Event - 18th November 2026

HGF Venture: Funding the Future

Join fellow life sciences founders, investors and business leaders for an evening of drinks and networking in Cambridge on the 18th November, 5-9pm. Featuring an investor-founder round table and an …

Event details

Designing the Exit: IP Strategy for Venture-Backed Biotech

In venture-built biotech, value is not created at the point of exit, but is designed into the asset from the very beginning. The earliest decisions made around a scientific discovery …

Read article

Five Questions VCs Should Ask About IP Before They Invest

Intellectual property diligence too often starts with the wrong question: how many patents does the company have? For venture investors, that is rarely the most revealing answer. The real issue …

Read article

Let's talk

If you would like to discuss how HGF could help you, contact one of our cell & gene therapy specialists.